With all the uncertainty of COVID-19, we hope you are safe and in good health. Ozgene is still here to meet your research needs.

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol and atherosclerosis in the absence of ApoE.

 Back to publications

2014

J Lipid Res. 2014 Sep 25. pii: jlr.M053207. [Epub ahead of print]

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol and atherosclerosis in the absence of ApoE.

B Ason;JW van der Hoorn;J Chan;E Lee;EJ Pieterman;KK Nguyen;M Di;S Shetterly;J Tang;WC Yeh;M Schwarz;JW Jukema;R Scott;SM Wasserman;HM Princen;S Jackson

Amgen, Inc, Thousand Oaks, CA, United States; TNO - Metabolic Health Research, Netherlands; Leiden University Medical Center, Netherlands.

Service type: Knockout mice

Abstract

Low density lipoprotein cholesterol (LDL-C) contributes to coronary heart disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases LDL-C by inhibiting LDL-C clearance. The therapeutic potential for PCSK9 inhibitors is highlighted by the fact that PCSK9 loss-of-function carriers exhibit 15-30% lower circulating LDL-C and a disproportionately lower risk (47-88%) of experiencing a cardiovascular event. Here, we utilized pcsk9-/- mice and an anti-PCSK9 antibody to study the role of the LDL-receptor (LDLR) and apolipoprotein E (ApoE) in PCSK9-mediated regulation of plasma cholesterol and atherosclerotic lesion development. We found that circulating cholesterol and atherosclerotic lesions were minimally modified in pcsk9-/- mice on either an LDLR- or ApoE-deficient background. Acute administration of an anti-PCSK9 antibody did not reduce circulating cholesterol in an ApoE-deficient background but did reduce circulating cholesterol (-45%) and triglycerides (-36%) in APOE*3Leiden.CETP mice, which contain mouse ApoE, human mutant APOE3*Leiden, and a functional LDLR. Chronic anti-PCSK9 antibody treatment in APOE*3Leiden.CETP mice resulted in a significant reduction in atherosclerotic lesion area (-91%) and reduced lesion complexity. Taken together, these results indicate that both LDLR and ApoE are required for PCSK9-inhibitor mediated reductions in atherosclerosis, as both are needed to increase hepatic LDLR expression.

View Publication